Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Holding BLFS?
Track your performance easily
BLFS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.50 - $28.88
Previous Close$27.39
Volume1.08M
Average Volume (3M)388.26K
Market Cap
$1.27B
Enterprise Value$1.28B
Total Cash (Recent Filing)$34.19M
Total Debt (Recent Filing)$39.27M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Mar 13, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding46,387,214
10 Day Avg. Volume276,113
30 Day Avg. Volume388,265
Standard Deviation0.20
R-Squared0.26
Alpha0.00379
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)10.30
Price to Cash Flow (P/CF)66.20
P/FCF Ratio66.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.34
Enterprise Value/Gross Profit27.28
Enterprise Value/Ebitda-81.60
Forecast
1Y Price Target
$30.20Price Target Upside10.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BioLife Solutions News
PremiumCompany Announcements
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Bulls Say, Bears Say
Bulls Say
Financial Performance And Strategic DivestituresThe sale of SciSafe generated $73M in cash, divested a non-core asset, and serves to improve the long-term financial profile of the Company.
Revenue Growth And Market ExpansionCell processing revenue showed significant growth, up 43% YoY, marking the fourth consecutive quarter of growth.
Strategic Focus And Market PositionBiolife is now focused on its 'sticky', high margin, recurring-revenue, cell processing platform and remains deeply entrenched within the Cell and Gene therapy sector with market share in excess of 70% of relevant commercially-approved therapies.
Bears Say
2024 Revenue ProjectionThe revenue guidance for 2024 was revised to a lower range to better reflect the divestiture of SciSafe.
Revenue GuidanceBioLife lowered revenue guidance to $98M-$100M, from $99M-$101M, to factor in the reduction of the SciSafe divestiture.
Stock Price TargetProjected revenues for the next 12 months are lowered, resulting in a reduced price target of $27 per share.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $14.50 and its highest was $28.88 in the past 12 months.
What is BioLife Solutions’s market cap?
Currently, no data Available
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Nov 12, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.038.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is -$0.08.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 46,387,215 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -9.019%.
Which hedge fund is a major shareholder of BioLife Solutions?
Among the largest hedge funds holding BioLife Solutions’s share is Royce & Associates LLC. It holds BioLife Solutions’s shares valued at 21M.
---
BioLife Solutions Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.20 (10.26% Upside)
$30.20 (10.26% Upside)
Hedge Fund Trend
Decreased
By 75.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.37%
12-Months-Change
Fundamentals
Return on Equity
-9.87%
Trailing 12-Months
Asset Growth
-7.17%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
---
BLFS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and margin expansion driven by the cell processing platform. The strategic divestiture of the SciSafe BioStorage business is expected to streamline operations and improve the company's financial position. However, the reduction in overall revenue guidance and the dependency on a small customer base are notable concerns.Read More>---
BLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
---
BLFS Stock 12 Month Forecast
Average Price Target
$30.20
▲(10.26% Upside)
Technical Analysis
Best Analysts Covering BLFS
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+54.78%
assigned a buy rating last month
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +54.78% per trade.
---